Didn't mean to indicate Dr. Pourhassan and team are walking blind as I believe they've already had tremendous experience with the FDA and knowledge about what's required, the process and what's expected on and from both sides but I think the so-called Type A meeting at this point is not anything CytoDyn has yet experienced... and if someone on these boards has actual interaction with the FDA about such, then might be better for any company to go into such a meeting with some background about this specific meeting and what it may entail.
Market Data 
Markets 
